Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt.

doi:10.1021/JM00194A015

Paper

Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt.

Published Aug 1, 1979 · C. D. Jones, T. Suarez, E. Massey

Journal of medicinal chemistry

Q1 SJR score

46

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Acylation of the sodio anion of beta-tetralone with phenyl anisoate, followed by a Grignard reaction of the resultant 4 with 4-methoxyphenylmagnesium bromide, gave rise to two novel dihydronaphthalene isomers 5 and 6. Regioselective demethylation of either 5 or 6 by NaSEt produced [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone (7). Etherification of the phenolic group of 7 by N-(2-chloroethyl)pyrrolidine and subsequent methanesulfonate salt formation provided [3,4-dihydro-2-(4-methoxyphenyl)-1-maphthalenyl]]4-]2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, methane sulfonic acid salt (3). Potent antiestrogenic activity of 3 was demonstrated by both oral and subcutaneous administration to rats and mice. In vitro binding studies with rat uterine cytosol estrogen receptors indicate compound 3 has a very high binding affinity which exceeds that of estradiol.

Non-RCT

Animal Study

Study Snapshot

Compound 3 has a high binding affinity for estrogen receptors, with potent antiestrogenic activity, surpassing estradiol.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt.

Sign up to use Study Snapshot

References

Citations

Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.

The 4-nitrophenyl derivative of MPP shows potential as an estrogen receptor antagonist for breast cancer treatment without endometrial carcinoma complications.

Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations

This study identified novel small molecule therapeutics targeting estrogen receptors, offering potential for tamoxifen-resistant breast cancers and complementing existing anti-estrogen therapy.

The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators

The evolution of nonsteroidal antiestrogens into selective estrogen receptor modulators (SERMs) has led to improved women's health applications, including reduced breast cancer risk, osteoporosis, and menopausal hot flashes.

Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

The McMurry coupling reaction successfully synthesized tri- and tetra-arylethylene analogues, which show potential as cancer chemotherapeutic agents by inhibiting tubulin polymerization and cell growth in human cancer cell lines.

Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health

Fulvestrant shows promising therapeutic efficacy and minimal impact on bone integrity, making it a promising new option for hormonal treatment of breast cancer.

Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release

ICI effectively inhibits pituitary lactotroph proliferation and prolactin release by downregulating estrogen receptor, suggesting different mechanisms for cell proliferation and release.

Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.

WAY-169916, a pathway-selective estrogen receptor ligand, effectively inhibits NF-kappaB transcriptional activity without promoting conventional estrogenic effects, offering potential for treating chronic inflammatory diseases.